Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 165

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 165
---
 except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company or Merger Sub.

<div align='center'>Article V COVENANTS</div>

5.1 Conduct of Business by the Company and Merger Sub. Except (a)as expressly provided in this Agreement, (b)as described in Schedule ‎5.1to this Agreement, (c)with the prior written consent of TELI (which consent shall not be unreasonably withheld, conditioned or delayed), during the period from the date hereof to the Effective Time or the earlier termination of this Agreement in accordance with ‎Article VIIbelow (such period, the “ Interim Period”), the Company and Merger Sub will: (i)not take any action that would or would reasonably be expected to prevent, materially impair or materially delay the ability of the Company, Merger Sub or TELI to consummate the transactions contemplated by this Agreement or the other Transaction Agreements, (ii)conduct its operations in all material respects in the ordinary and usual course of business consistent with past practice, and (iii)use their reasonable best efforts to preserve intact its and Merger Sub’s corporate existence. Without limiting the generality of the foregoing, except as otherwise expressly provided in this Agreement or as described in Schedule ‎5.1to this Agreement, during the Interim Period, none of the Company nor Merger Sub will (unless required by Applicable Law after consultation with counsel and TELI), without the prior written consent of TELI (which shall not be unreasonably withheld or delayed):

5.1.0 amend or authorize any amendments to the terms of any of their outstanding securities or its governing or organizational documents, or to the governing or organizational documents of Merger Sub;

5.1.1 issue, sell, deliver, pledge, dispose of, encumber or transfer or agree or commit to do or authorize any of the foregoing with respect to (whether through the issuance or granting of options, warrants, commitments, subscriptions, rights to purchase or otherwise) any stock of any class or any other equity securities or equity equivalents (including any stock options or stock appreciation rights) of the Company except for the issuance and sale of Company Common Stock pursuant to Company Equity Awards granted under the Company Plans prior to the date hereof and issuance of Company Equity Awards to new employees in the ordinary course of business consistent with past practice;

5.1.2 split, combine or reclassify